Shares of Relmada Therapeutics (NASDAQ: RLMD), a clinical-stage biopharmaceutical company, popped in response to a positive clinical trial readout with the company's lead candidate. Investors excited about REL-1017's positive human abuse potential trial results pushed the stock 37% higher at its peak this morning. Relmada Therapeutics has settled down since its early morning pop.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting